<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Asthma in pregnancy.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American College of Obstetricians and Gynecologists (ACOG). Asthma in pregnancy. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2008 Feb. 8 p.&amp;nbsp;(ACOG practice bulletin; no. 90).&amp;nbsp; [26 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The American College of Obstetricians and Gynecologists (ACOG) reaffirmed the currency of this guideline in 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: General physical examination  (89.7)"/><FieldValue Value="MSH: Adrenergic beta-Agonists ; Albuterol ; Asthma ; Breast Feeding ; Budesonide ; Counseling ; Cromolyn Sodium ; Environment, Controlled ; Fetal Monitoring ; Forced Expiratory Volume ; Immunotherapy ; Leukotriene Antagonists ; Medical History Taking ; Nebulizers and Vaporizers ; Neonatal Screening ; Patient Care Planning ; Patient Discharge ; Peak Expiratory Flow Rate ; Physical Examination ; Pregnancy Complications ; Prenatal Care ; Respiratory Function Tests ; Self Care ; Severity of Illness Index ; Spirometry ; Theophylline ; Ultrasonography, Prenatal "/><FieldValue Value="MTH: Adrenergic beta-Agonists ; Asthma ; Breast Feeding ; Counseling ; Cromolyn Sodium ; Fetal Monitoring ; Forced expiratory volume function ; Immunotherapy ; Leukotriene Antagonists ; Patient Discharge ; Peak expiratory flow rate measurement ; physical examination ; Pregnancy Complications ; Prenatal care ; Respiratory Function Tests ; Self-care interventions ; Theophylline "/><FieldValue Value="PDQ: budesonide ; theophylline "/><FieldValue Value="SNOMEDCT_US: Albuterol  (372897005); Albuterol  (91143003); Antenatal care  (424525001); Asthma  (195967001); Beta-adrenoceptor agonist  (349920008); Beta-adrenoceptor agonist  (373227004); Breast fed  (169741004); Budesonide  (108622005); Budesonide  (395726003); Counseling  (129441002); Counseling  (409063005); Cromolyn sodium  (387221005); Cromolyn sodium  (40652001); Forced expired volume  (165041004); Immunological therapy  (76334006); Leukotriene receptor inhibitor  (108616001); Leukotriene receptor inhibitor  (372517002); Measurement of respiratory function  (23426006); Neonatal screening  (60151004); Patient discharge  (58000006); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Self-care interventions  (384758001); Spirometry  (127783003); Step down change in asthma management plan  (390878008); Step up change in asthma management plan  (390877003); Theophylline  (372810006); Theophylline  (66493003)"/><FieldValue Value="UMD: Nebulizers, Nonheated  (15-045)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Asthma in pregnancy&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Pulmonary Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;To aid practitioners in making decisions about appropriate obstetric and gynecologic care&lt;/li&gt;&#xD;&#xA;&lt;li&gt;To review the best available evidence about the management of asthma during pregnancy&lt;/li&gt;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Pregnant women with asthma&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Evaluation and Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;ol start=&quot;1&quot; type=&quot;1&quot;&gt;&#xD;&#xA;&lt;li&gt;Subjective assessment&#xD;&#xA;&#xD;&#xA;&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;Physical examination&lt;/li&gt;&#xD;&#xA;&lt;li&gt;History of symptoms, temporal relationships, triggers&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Pulmonary impairment: asthma severity classification&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Response to asthma therapy&lt;/li&gt;&lt;/ul&gt;&#xD;&#xA;&lt;/li&gt;&#xD;&#xA;&#xD;&#xA;&lt;li&gt;Pulmonary function tests&#xD;&#xA;&#xD;&#xA;&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;Spirometry: and forced expiratory volume in the first second of expiration (FEV&lt;sub&gt;1&lt;/sub&gt;)&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Peak expiratory flow rate (PEFR)&lt;/li&gt;&lt;/ul&gt;&#xD;&#xA;&lt;/li&gt;&#xD;&#xA;&#xD;&#xA;&lt;li&gt;Fetal assessment during acute asthma&lt;/li&gt;&lt;/ol&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management and Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;ol start=&quot;1&quot; type=&quot;1&quot;&gt;&#xD;&#xA;&lt;li&gt;Allergen immunotherapy (allergy shots) during pregnancy (considered but not recommended unless patient is at or near maintenance dose)&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Pharmacologic approaches&#xD;&#xA;&#xD;&#xA;&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;Inhaled short-acting beta&lt;sub&gt;2&lt;/sub&gt;-agonist (albuterol) as rescue therapy&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Inhaled corticosteroids (budesonide) as long-term controller therapy&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Alternative add-on medications (long-acting beta&lt;sub&gt;2&lt;/sub&gt;-agonists, cromolyn, leukotriene antagonist, theophylline)&lt;/li&gt;&lt;/ul&gt;&#xD;&#xA;&lt;/li&gt;&#xD;&#xA;&#xD;&#xA;&lt;li&gt;Step therapy medical management of asthma&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Emphasizing asthma self-management skills&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Nonpharmacologic approaches&#xD;&#xA;&#xD;&#xA;&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;Identifying and controlling or avoiding allergens and irritants&lt;/li&gt;&lt;/ul&gt;&#xD;&#xA;&lt;/li&gt;&#xD;&#xA;&#xD;&#xA;&lt;li&gt;Discharge regimen&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Fetal surveillance&#xD;&#xA;&#xD;&#xA;&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;Ultrasound&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Antenatal fetal testing&lt;/li&gt;&lt;/ul&gt;&#xD;&#xA;&lt;/li&gt;&#xD;&#xA;&#xD;&#xA;&lt;li&gt;Counseling about breastfeeding&lt;/li&gt;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;Maternal and perinatal pregnancy outcomes&#xD;&#xA;&#xD;&#xA;&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;Prematurity&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Need for cesarean delivery&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Pre-eclampsia&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Fetal growth restriction&lt;/li&gt;&lt;/ul&gt;&#xD;&#xA;&lt;/li&gt;&#xD;&#xA;&#xD;&#xA;&lt;li&gt;Maternal morbidity and mortality&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Drug side effects&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Hospitalization rate&lt;/li&gt;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;2008 Original Guideline&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MEDLINE database, the Cochrane Library, and the American College of Obstetricians and Gynecologists' own internal resources and documents were used to conduct a literature search to locate relevant articles published between January 1985 and March 2007. The search was restricted to articles published in the English language. Priority was given to articles reporting results of original research, although review articles and commentaries also were consulted. Abstracts of research presented at symposia and scientific conferences were not considered adequate for inclusion in this document. Guidelines published by organizations or institutions such as the National Institutes of Health and the American College of Obstetricians and Gynecologists were reviewed, and additional studies were located by reviewing bibliographies of identified articles.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2012 Reaffirmation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The NCBI database was searched from 2008 to 2012. Committee members conducted a literature search with the assistance from the ACOG Resource Center staff who routinely perform the Practice Bulletin literature searches.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Studies were reviewed and evaluated for quality according to the method outlined by the U.S. Preventive Services Task Force:&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt; Evidence obtained from at least one properly designed randomized controlled trial.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-1&lt;/strong&gt; Evidence obtained from well-designed controlled trials without randomization.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-2&lt;/strong&gt; Evidence obtained from well-designed cohort or case&amp;#8211;control analytic studies, preferably from more than one center or research group.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-3&lt;/strong&gt; Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III&lt;/strong&gt; Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;2008 Original Guideline&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Analysis of available evidence was given priority in formulating recommendations. When reliable research was not available, expert opinions from obstetrician&amp;ndash;gynecologists were used. See also the &quot;Rating Scheme for the Strength of Recommendations&quot; field regarding Grade C recommendations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2012 Reaffirmation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Committee on Practice Bulletins - Obstetrics met in October 2012 and reaffirmed this document. A committee member reviewed the document and new literature on the topic. The document was then reviewed by the committee and the committee agreed that it is current and accurate.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Based on the highest level of evidence found in the data, recommendations are provided and graded according to the following categories:&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A&lt;/strong&gt; &amp;#8212; Recommendations are based on good and consistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B&lt;/strong&gt; &amp;#8212; Recommendations are based on limited or inconsistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C&lt;/strong&gt; &amp;#8212; Recommendations are based primarily on consensus and expert opinion.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Practice Bulletins are validated by two internal clinical review panels composed of practicing obstetrician-gynecologists generalists and sub-specialists. The final guidelines are also reviewed and approved by the American College of Obstetricians and Gynecologists (ACOG) Executive Board.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The grades of evidence (I-III) and levels of recommendations (A-C) are defined at the end of &amp;quot;Major Recommendations&amp;quot; field.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;The following recommendations and conclusions are based on limited or inconsistent scientific evidence (Level B)&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;It is safer for pregnant women with asthma to be treated with asthma medications than it is for them to have asthma symptoms and exacerbations.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Clinical evaluation of asthma includes subjective assessments and pulmonary function tests.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;The ultimate goal of asthma therapy in pregnancy is maintaining adequate oxygenation of the fetus by preventing hypoxic episodes in the mother.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;The step-care therapeutic approach (see box below) increases the number and dosage of medications with increasing asthma severity.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Inhaled corticosteroids are first-line controller therapy for persistent asthma during pregnancy.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Budesonide is the preferred inhaled corticosteroid for use during pregnancy.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Inhaled albuterol is recommended rescue therapy for pregnant women with asthma.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Identifying and controlling or avoiding factors such as allergens and irritants, particularly tobacco smoke, can lead to improved maternal well-being with less need for medication.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Continuation of immunotherapy is recommended in patients who are at or near a maintenance dose, not experiencing adverse reactions to the injections, and apparently deriving clinical benefit.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Use of prednisone, theophylline, antihistamines, inhaled corticosteroids, beta&lt;sub&gt;2&lt;/sub&gt;-agonists, and cromolyn is not contraindicated for breastfeeding.&lt;/li&gt;&lt;/ul&gt;&#xD;&#xA;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; summary=&quot;Table. Step Therapy Medical Management of Asthma During Pregnancy&quot;&gt;&#xD;&#xA;&lt;tr&gt;&#xD;&#xA;&lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;&#xD;&#xA;&lt;strong&gt;Step Therapy Medical Management of Asthma During Pregnancy&lt;/strong&gt;&#xD;&#xA;&lt;br /&gt;&lt;br /&gt;&#xD;&#xA;&#xD;&#xA;&lt;strong&gt;Mild Intermittent Asthma&lt;/strong&gt;&#xD;&#xA;&#xD;&#xA;&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;No daily medications, albuterol as needed&lt;/li&gt;&lt;/ul&gt;&#xD;&#xA;&#xD;&#xA;&lt;strong&gt;Mild Persistent Asthma&lt;/strong&gt;&#xD;&#xA;&#xD;&#xA;&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;Preferred &amp;#8211; Low-dose inhaled corticosteroid&lt;/li&gt;&#xD;&#xA;&#xD;&#xA;&lt;li&gt;Alternative &amp;#8211; Cromolyn, leukotriene receptor antagonist, or theophylline (serum level 5 to 12 mcg/mL)&lt;/li&gt;&lt;/ul&gt;&#xD;&#xA;&#xD;&#xA;&lt;strong&gt;Moderate Persistent Asthma&lt;/strong&gt;&#xD;&#xA;&#xD;&#xA;&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;Preferred &amp;#8211; Low-dose inhaled corticosteroid and salmeterol or medium-dose inhaled corticosteroid or (if needed) medium-dose inhaled corticosteroid and salmeterol&lt;/li&gt;&#xD;&#xA;&#xD;&#xA;&lt;li&gt;Alternative &amp;#8211; Low-dose or (if needed) medium-dose inhaled corticosteroid and either leukotriene receptor antagonist or theophylline (serum level 5 to 12 mcg/mL)&lt;/li&gt;&lt;/ul&gt;&#xD;&#xA;&#xD;&#xA;&lt;strong&gt;Severe Persistent Asthma&lt;/strong&gt;&#xD;&#xA;&#xD;&#xA;&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;Preferred &amp;#8211; High-dose inhaled corticosteroid and salmeterol and (if needed) oral corticosteroid&lt;/li&gt;&#xD;&#xA;&#xD;&#xA;&lt;li&gt;Alternative &amp;#8211; High-dose inhaled corticosteroid and theophylline (serum level 5 to 12 mcg/mL) and oral corticosteroid if needed&lt;/li&gt;&lt;/ul&gt;&#xD;&#xA;&lt;/td&gt;&#xD;&#xA;&lt;/tr&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;The following recommendations and conclusions are based primarily on consensus and expert opinion (Level C)&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;Asthma self-management skills, including self-monitoring, correct use of inhalers, and following a plan for long-term management of asthma and promptly handling signs of worsening asthma, enhance asthma control.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;For pulmonary function assessment of patients during outpatient visits, spirometry is preferable, but peak expiratory flow measurement with a peak flow meter also is sufficient.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Ultrasound examinations and antenatal fetal testing should be considered for women who have moderate or severe asthma during pregnancy.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Pregnant patients with asthma, even those with mild or well-controlled disease, need to be monitored with peak expiratory flow rate (PEFR) and forced expiratory volume in the first second of expiration (FEV&lt;sub&gt;1&lt;/sub&gt;) testing as well as by observing their symptoms during pregnancy.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Routine evaluation of pulmonary function in pregnant women with persistent asthma is recommended.&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Because pulmonary function and asthma severity may change during the course of pregnancy, routine evaluation of pulmonary function in pregnant women with persistent asthma is recommended.&lt;/li&gt;&lt;/ul&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;u&gt;Definitions&lt;/u&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grades of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;I&lt;/strong&gt; Evidence obtained from at least one properly designed randomized controlled trial.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-1&lt;/strong&gt; Evidence obtained from well-designed controlled trials without randomization.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-2&lt;/strong&gt; Evidence obtained from well-designed cohort or case&amp;#8211;control analytic studies, preferably from more than one center or research group.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;II-3&lt;/strong&gt; Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments also could be regarded as this type of evidence.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;III&lt;/strong&gt; Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A&lt;/strong&gt; &amp;#8212; Recommendations are based on good and consistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B&lt;/strong&gt; &amp;#8212; Recommendations are based on limited or inconsistent scientific evidence.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C&lt;/strong&gt; &amp;#8212; Recommendations are based primarily on consensus and expert opinion.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see &amp;quot;Major Recommendations&amp;quot;).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate management of asthma during pregnancy&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Drug side effects&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Risk-benefit considerations do not usually favor beginning allergen immunotherapy during pregnancy.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;These guidelines should not be construed as dictating an exclusive course of treatment or procedure. Variations in practice may be warranted based on the needs of the individual patient, resources, and limitations unique to the institution or type of practice.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American College of Obstetricians and Gynecologists (ACOG). Asthma in pregnancy. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2008 Feb. 8 p.&amp;nbsp;(ACOG practice bulletin; no. 90).&amp;nbsp; [26 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2008 Feb (reaffirmed 2012)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American College of Obstetricians and Gynecologists - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American College of Obstetricians and Gynecologists (ACOG)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins - Obstetrics&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The American College of Obstetricians and Gynecologists (ACOG) reaffirmed the currency of this guideline in 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: None available&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available for purchase from the American College of Obstetricians and Gynecologists (ACOG) Distribution Center, PO Box 933104, Atlanta, GA 31193-3104; telephone, 800-762-2264, ext. 192; e-mail: &lt;a href=&quot;mailto:sales@acog.org&quot;&gt;sales@acog.org&lt;/a&gt;. The ACOG Bookstore is available online at the &lt;a href=&quot;http://www.acog.org/bookstore/&quot; title=&quot;ACOG Web site&quot; target=&quot;_blank&quot;&gt;ACOG Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Proposed performance measures are included in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on July 30, 2008. The information was verified by the guideline developer on August 20, 2008. This summary was updated by ECRI Institute on May 14, 2010 following the U.S. Food and Drug Administration (FDA) advisory on Long-Acting Beta-Agonists (LABAs). The currency of the guideline was reaffirmed by the developer in 2012 and this summary was updated by ECRI Institute on March 7, 2014.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
